Usage Patterns of GlucoNote, a Self-Management Smartphone App, Based on ResearchKit for Patients With Type 2 Diabetes and Prediabetes.
diabetes mellitus
mHealth
self-management
telemedicine
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
24 04 2019
24 04 2019
Historique:
received:
10
01
2019
accepted:
30
03
2019
revised:
11
03
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
25
4
2019
Statut:
epublish
Résumé
Preventing progression from prediabetes to diabetes-or slowing the progression of diabetes-is an urgent task worldwide. Previous studies have shown that mobile health (mHealth) may powerfully support self-management for patients with type 2 diabetes. Certainly, mHealth improves health care efficiency and gives patients convenient access to self-management of their own health. Many health care apps are available right now, and their use in clinical studies with large-scale real-life data is expected. However, the usage patterns of those apps-especially in the absence of intervention by medical professionals-remain unknown. We developed GlucoNote, an app that uses Apple's ResearchKit to support self-management for patients with type 2 diabetes and prediabetes; the app does not require prescription or intervention by medical professionals. We evaluated its usage patterns via a remotely conducted study. iPhone users across Japan who have type 2 diabetes or prediabetes were free to download GlucoNote and to participate in the study after they provided consent electronically on the app. The 522 users who enrolled in the study within 1 year of its release were analyzed. We analyzed the retention rates of 357 participants who recorded at least 1 of 4 items-body weight, blood sugar, blood pressure, or dietary information. Characteristics of participants who used GlucoNote longer than 4 weeks (robust users) were compared with those of participants who did not (nonrobust users). The changes among robust users were evaluated. The median observation and retention durations were 382 days (interquartile range [IQR] 275-423) and 8 days (IQR 1-63), respectively. The retention rates for 2 days and for 4, 8, and 12 weeks were 0.627 (95% CI 0.575-0.675), 0.353 (0.304-0.403), 0.272 (0.227-0.319), and 0.220 (0.179-0.265), respectively. Men were more likely to be robust users than women (P=.02). At week 0, robust users were more likely than nonrobust users to have a higher daily energy intake (median 1595 [IQR 1198-1788] kcal vs 1451 [IQR 769-1657] kcal; P=.04) and have higher daily step counts (median 6108 [IQR 3797-9227] vs 5171 [IQR 2885-7258]; P=.001). Among robust users, body weight decreased from weeks 0 to 4 (mean 71.3 [SD 14.1] kg to 70.8 [SD 13.9] kg; P=.002) by mean 0.6% (SD 1.6). GlucoNote offered a valuable opportunity to evaluate usage patterns of apps. Future challenges include improving low retention rates and evaluating their effects.
Sections du résumé
BACKGROUND
Preventing progression from prediabetes to diabetes-or slowing the progression of diabetes-is an urgent task worldwide. Previous studies have shown that mobile health (mHealth) may powerfully support self-management for patients with type 2 diabetes. Certainly, mHealth improves health care efficiency and gives patients convenient access to self-management of their own health. Many health care apps are available right now, and their use in clinical studies with large-scale real-life data is expected. However, the usage patterns of those apps-especially in the absence of intervention by medical professionals-remain unknown.
OBJECTIVE
We developed GlucoNote, an app that uses Apple's ResearchKit to support self-management for patients with type 2 diabetes and prediabetes; the app does not require prescription or intervention by medical professionals. We evaluated its usage patterns via a remotely conducted study.
METHODS
iPhone users across Japan who have type 2 diabetes or prediabetes were free to download GlucoNote and to participate in the study after they provided consent electronically on the app. The 522 users who enrolled in the study within 1 year of its release were analyzed. We analyzed the retention rates of 357 participants who recorded at least 1 of 4 items-body weight, blood sugar, blood pressure, or dietary information. Characteristics of participants who used GlucoNote longer than 4 weeks (robust users) were compared with those of participants who did not (nonrobust users). The changes among robust users were evaluated.
RESULTS
The median observation and retention durations were 382 days (interquartile range [IQR] 275-423) and 8 days (IQR 1-63), respectively. The retention rates for 2 days and for 4, 8, and 12 weeks were 0.627 (95% CI 0.575-0.675), 0.353 (0.304-0.403), 0.272 (0.227-0.319), and 0.220 (0.179-0.265), respectively. Men were more likely to be robust users than women (P=.02). At week 0, robust users were more likely than nonrobust users to have a higher daily energy intake (median 1595 [IQR 1198-1788] kcal vs 1451 [IQR 769-1657] kcal; P=.04) and have higher daily step counts (median 6108 [IQR 3797-9227] vs 5171 [IQR 2885-7258]; P=.001). Among robust users, body weight decreased from weeks 0 to 4 (mean 71.3 [SD 14.1] kg to 70.8 [SD 13.9] kg; P=.002) by mean 0.6% (SD 1.6).
CONCLUSIONS
GlucoNote offered a valuable opportunity to evaluate usage patterns of apps. Future challenges include improving low retention rates and evaluating their effects.
Identifiants
pubmed: 31017586
pii: v7i4e13204
doi: 10.2196/13204
pmc: PMC6505564
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13204Informations de copyright
©Satoko Yamaguchi, Kayo Waki, Yasuhito Nannya, Masaomi Nangaku, Takashi Kadowaki, Kazuhiko Ohe. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 24.04.2019.
Références
Clin Diabetes. 2017 Jan;35(1):27-34
pubmed: 28144043
J R Soc Med. 2015 Aug;108(8):294-6
pubmed: 26268915
JMIR Mhealth Uhealth. 2017 Mar 14;5(3):e35
pubmed: 28292740
J Diabetes. 2011 Jun;3(2):147-52
pubmed: 21599868
J Am Diet Assoc. 2011 Jan;111(1):92-102
pubmed: 21185970
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Acad Med. 2017 Feb;92(2):157-160
pubmed: 27119325
Obes Res Clin Pract. 2014 Sep-Oct;8(5):e466-75
pubmed: 25263836
J Diabetes Sci Technol. 2014 Mar 13;8(2):209-215
pubmed: 24876569
BMC Obes. 2014 Oct 14;1:22
pubmed: 26217509
JMIR Mhealth Uhealth. 2017 Mar 01;5(3):e4
pubmed: 28249834
Cyberpsychol Behav. 2005 Feb;8(1):21-31
pubmed: 15738690
Nat Biotechnol. 2017 Apr;35(4):354-362
pubmed: 28288104
Diabetes Care. 2006 Sep;29(9):2102-7
pubmed: 16936160
JMIR Mhealth Uhealth. 2016 Jul 26;4(3):e87
pubmed: 27460502
JMIR Mhealth Uhealth. 2018 Sep 13;6(9):e177
pubmed: 30213779
Sci Data. 2016 Mar 03;3:160011
pubmed: 26938265
J Cardiovasc Nurs. 2013 Jul-Aug;28(4):320-9
pubmed: 22635061
J Diabetes Sci Technol. 2015 May;9(3):534-40
pubmed: 25883164